Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer

NCT03137264 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03137264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03137264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 24, 2017
Completion date
November 10, 2018
Enrollment
44 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer